{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-156202","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2024-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.486602+00:00","generated_at":"2026-06-01T05:55:29.649851+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Quince Therapeutics shareholders approve reverse stock split and elect three directors","bullets":["Approved 1-for-10 reverse stock split with 31,461,878 votes for, 1,019,669 against, 78,724 abstentions.","Elected Class II directors Dirk Thye, David Lamond, and Luca Benatti to serve until 2027 annual meeting.","Ratified BDO USA as independent registered accounting firm for fiscal year ending Dec 31, 2024.","Advisory say-on-pay approved: 17,945,554 for, 429,833 against, 94,767 abstentions (14,090,117 broker non-votes)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-156202","json":"https://secwatch.observer/filing/0001193125-24-156202.json","markdown":"https://secwatch.observer/filing/0001193125-24-156202.md","text":"https://secwatch.observer/filing/0001193125-24-156202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312524156202/0001193125-24-156202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312524156202/d844037d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:55:29.649851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}